SynthesisBioMed research international2014
Vasopressin in hemorrhagic shock: a systematic review and meta-analysis of randomized animal trials.
Synthesis in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- A Systematic Review of Neuroprotective Strategies during Hypovolemia and Hemorrhagic Shock.International journal of molecular sciences · 2017Pooled it
- Vasopressin Improves Cerebral Perfusion Pressure but Not Cerebral Blood Flow or Tissue Oxygenation in Patients with Subarachnoid Hemorrhage and Norepinephrine-Refractory Hypotension: A Preliminary Evaluation.Journal of clinical medicine · 2025Article
- Intramuscular vasopressin: A feasible intervention for prehospital hemodynamic stabilization in porcine hemorrhagic shock and whole blood transfusion.Transfusion · 2025Article
- Effects of Vasopressin Receptor Agonists during the Resuscitation of Hemorrhagic Shock: A Systematic Review and Meta-Analysis of Experimental and Clinical Studies.Journal of personalized medicine · 2023Article
- Management of Hemorrhagic Shock: Physiology Approach, Timing and Strategies.Journal of clinical medicine · 2022Review
- Article
- Effects of the Kv7 voltage-activated potassium channel inhibitor linopirdine in rat models of haemorrhagic shock.Clinical and experimental pharmacology & physiology · 2018Article
- Evaluation of capillary leakage after vasopressin resuscitation in a hemorrhagic shock model.World journal of emergency surgery : WJES · 2018Article
- Role of vasopressin in current anesthetic practice.Korean journal of anesthesiology · 2017Review
- Infrarenal aortic clamp reviving a patient from acute surgical haemorrhagic shock: a novel management technique.BMJ case reports · 2016Article
- New perspectives of volemic resuscitation in polytrauma patients: a review.Burns & trauma · 2016Review
- Pharmacological targeting of chemokine (C-X-C motif) receptor 4 in porcine polytrauma and hemorrhage models.The journal of trauma and acute care surgery · 2016Article
- What's new in vasopressin?Intensive care medicine · 2015Review
- Article
- Vasopressors: Do they have any role in hemorrhagic shock?Journal of anaesthesiology, clinical pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe latest European guidelines for the management of hemorrhagic shock suggest the use of vasopressors (norepinephrine) in order to restore an adequate mean arterial pressure when fluid resuscitation therapy fails to restore blood pressure. The administration of arginine vasopressin (AVP), or its analogue terlipressin, has been proposed as an alternative treatment in the early stages of hypovolemic shock.
designA meta-analysis of randomized controlled animal trials.
participantsA total of 433 animals from 15 studies were included.
interventionsThe ability of AVP and terlipressin to reduce mortality when compared with fluid resuscitation therapy, other vasopressors (norepinephrine or epinephrine), or placebo was investigated. MEASUREMENTS AND MAIN
resultsPooled estimates showed that AVP and terlipressin consistently and significantly improve survival in hemorrhagic shock (mortality: 26/174 (15%) in the AVP group versus 164/259 (63%) in the control arms; OR=0.09; 95% CI 0.05 to 0.15; P for effect<0.001; P for heterogeneity=0.30; I2=14%).
conclusionsResults suggest that AVP and terlipressin improve survival in the early phases of animal models of hemorrhagic shock. Vasopressin seems to be more effective than all other treatments, including other vasopressor drugs. These results need to be confirmed by human clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.